You are here: Industry Insights > Telix

News List

Illuccix® Approved in the United Kingdom PR Newswire
February 13, 2025
Telix today Announces that UK Medicines and MHRA has Approved the MAA for its prostate cancer medicine.
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform PRNewswire
January 31, 2025
Telix completes the acquisition from ImaginAb, getting a drug pipeline and a biologics technology platform.
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging PRNewswire
December 30, 2024
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies.
Ryoichi Tanaka Joins Telix Japan as COO firstwordpharma
August 06, 2021
Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') is pleased to announce that Mr. Ryoichi Tanaka has joined the Telix Japan leadership team in the role of Chief Operating Officer and Head of Business Development.
Helen Hovenga Joins Telix as Chief People Officer firstwordpharma
August 04, 2021
Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') is pleased to announce that Ms. Helen Hovenga has joined the Telix executive team in the role of Chief People Officer (CPO).
Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations firstwordpharma
July 12, 2021
Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') is pleased to announce that Ms. Kyahn Williamson has joined the Telix executive leadership team in the role of Senior Vice President of Corporate Communications and Investor Relations.
Telix, Eczacıbaşı-Monrol Sign Manufacturing Agreement contractpharma
June 21, 2019
Working together for six months on tech transfer of radiopharmaceutical manufacturing methods for TLX250-CDx.
Telix, Nihon collaborate on renal cancer imaging for Japanese market biospectrumasia
August 21, 2018
The agreement between Telix and NMP is focused on Telix’s TLX250 imaging program for renal cancer with Positron Emission Tomography (PET).